company background image
ATXS logo

Astria Therapeutics NasdaqGM:ATXS Stock Report

Last Price

US$13.60

Market Cap

US$747.9m

7D

-14.9%

1Y

7.6%

Updated

28 Mar, 2024

Data

Company Financials +

Astria Therapeutics, Inc.

NasdaqGM:ATXS Stock Report

Market Cap: US$747.9m

ATXS Stock Overview

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.

ATXS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Astria Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Astria Therapeutics
Historical stock prices
Current Share PriceUS$13.60
52 Week HighUS$16.90
52 Week LowUS$4.26
Beta0.72
1 Month Change-2.72%
3 Month Change77.08%
1 Year Change7.59%
3 Year Change-21.02%
5 Year Change-72.92%
Change since IPO-98.26%

Recent News & Updates

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

Recent updates

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Dec 10
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Jul 27
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Apr 03
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Jul 15

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Jun 30

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Jun 15

Catabasis Pharma shares surge after Quellis Biosciences deal

Jan 29

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Dec 10
Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 29

Shareholder Returns

ATXSUS BiotechsUS Market
7D-14.9%0.9%0.4%
1Y7.6%10.3%28.8%

Return vs Industry: ATXS underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: ATXS underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is ATXS's price volatile compared to industry and market?
ATXS volatility
ATXS Average Weekly Movement12.5%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ATXS's share price has been volatile over the past 3 months.

Volatility Over Time: ATXS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200859Jill Milnehttps://www.astriatx.com

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.

Astria Therapeutics, Inc. Fundamentals Summary

How do Astria Therapeutics's earnings and revenue compare to its market cap?
ATXS fundamental statistics
Market capUS$747.94m
Earnings (TTM)-US$72.89m
Revenue (TTM)n/a

0.0x

P/S Ratio

-10.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATXS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$72.89m
Earnings-US$72.89m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.33
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ATXS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.